DexCom (NASDAQ:DXCM) Director Nicholas Augustinos Sells 1,550 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos sold 1,550 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $84.02, for a total value of $130,231.00. Following the sale, the director directly owned 35,832 shares in the company, valued at approximately $3,010,604.64. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nicholas Augustinos also recently made the following trade(s):

• On Tuesday, September 15th, Nicholas Augustinos sold 6,539 shares of DexCom stock. The stock was sold at an average price of $84.04, for a total value of $549,537.56.

DexCom Trading Up 1.0%

DXCM stock opened at $87.34 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59. The business has a 50 day simple moving average of $83.52 and a two-hundred day simple moving average of $73.07. The company has a market capitalization of $32.96 billion, a price-to-earnings ratio of 34.52, a PEG ratio of 1.45 and a beta of 1.42.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.48 EPS. Research analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Expanded leadership role: CFO Jereme Sylvain will also serve as chief operating officer, potentially improving coordination between DexCom’s financial and operational functions as the company expands its continuous glucose-monitoring business. DexCom CFO Jereme Sylvain to Take Additional Role of COO
• Positive Sentiment: Strong recent financial results: DexCom’s latest quarterly report exceeded expectations, with earnings per share of $0.70 versus the $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13.1% year over year, supporting the growth outlook for its G7 and other CGM products.
• Positive Sentiment: Generally favorable analyst view: The stock carries a “Moderate Buy” consensus rating, with recent bullish targets including $95 from Stifel, $96 from UBS and $105 from Robert W. Baird. The average published target is $88.71, suggesting relatively limited but still positive upside based on the cited estimates.
• Neutral Sentiment: Insider selling appears scheduled: EVP Michael Brown sold 1,700 shares, while Director Nicholas Augustinos sold a combined 8,089 shares. Because the transactions were conducted under pre-arranged trading plans, they may reflect routine diversification rather than a negative view of DexCom’s prospects. DexCom insider transaction filing
• Negative Sentiment: Multiple insider sales could weigh on sentiment: The recent sales, including EVP Jereme Sylvain’s disposal of 3,638 shares for approximately $303,000, add a short-term cautionary signal even though the executives retained substantial holdings. DexCom insider selling report

Analyst Ratings Changes

DXCM has been the topic of a number of research analyst reports. Truist Financial set a $93.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Stifel Nicolaus set a $95.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Friday, July 31st. TD Cowen reaffirmed a “buy” rating on shares of DexCom in a report on Friday, July 31st. Piper Sandler reissued an “overweight” rating and issued a $95.00 target price (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Finally, UBS Group set a $96.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $88.71.

Institutional Trading of DexCom

A number of large investors have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of DexCom by 15.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock worth $758,487,000 after purchasing an additional 1,515,702 shares during the last quarter. Geode Capital Management LLC lifted its holdings in DexCom by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after buying an additional 42,411 shares in the last quarter. Norges Bank bought a new stake in DexCom during the 4th quarter valued at about $483,356,000. Janus Henderson Group PLC boosted its position in DexCom by 32.3% in the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock valued at $166,077,000 after buying an additional 645,534 shares during the period. Finally, Legal & General Group Plc purchased a new stake in DexCom in the 2nd quarter valued at about $173,237,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.